secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0000939767-22-000108
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis Q3 revenue $411.7M; cabozantinib franchise up 39% YoY; GAAP EPS $0.23
------------------------------------------------------------------------------

- Total revenues $411.7M (up 25% YoY); cabozantinib net product revenue $366.5M (+39% YoY).
- GAAP net income $73.2M ($0.23 diluted EPS) vs $38.2M ($0.12) prior year; non-GAAP EPS $0.31.
- Announced option deals with Cybrexa and Sairopa to access early-stage oncology assets.
- Cash and investments $2.1B at quarter end, up from $1.9B at Dec 2021.
- R&D expenses $198.8M (up from $163.4M); SG&A $115.0M (up from $101.6M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976722000108/0000939767-22-000108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976722000108/exel-20221101.htm
  HTML page:      https://secwatch.observer/filing/0000939767-22-000108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer